Mantra Capital Limited (formerly Savani Financials Limited) has successfully completed a significant fundraising initiative through the allotment of secured non-convertible debentures worth ₹2.00 crores. The Capital and Fundraising Committee of the Board of Directors approved this allotment during their meeting held on January 20, 2026, marking an important step in the company's capital expansion strategy.

Debenture Allotment Details

The committee approved the allotment of 2,000 secured, unlisted, and unrated non-convertible debentures with specific terms designed to attract investors while providing the company with necessary capital.

Meeting and Regulatory Compliance

The Capital and Fundraising Committee meeting commenced at 5:30 PM and concluded at 7:15 PM on January 20, 2026. This allotment follows previous intimations dated November 12, 2025, and January 12, 2026, regarding the company's plans to raise funds through secured, unlisted, unrated non-convertible debentures on a private placement basis.

The allotment has been conducted in full compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also adhered to SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Key Features and Security

The non-convertible debentures offer several important features for both the company and investors:

• Unlisted Status: The NCDs will not be listed on any stock exchange
• Security Coverage: Secured with coverage up to 1x over the company's receivables
• No Special Rights: No special rights, interests, or privileges are attached to the instruments
• Clean Payment Record: No delays or defaults in payment history reported

Company Information

Mantra Capital Limited, formerly known as Savani Financials Limited, operates from its registered office located at 602, Samarth Vaibhav CHS Ltd., Off Link Road, Lokhandwala Complex, Andheri (West), Mumbai - 400053. The company holds CIN L67120MH1983PLC031614 and trades under the scrip code 511577 with the scrip name SAVFI on BSE Limited.

The successful completion of this NCD allotment demonstrates the company's ability to access capital markets and execute its fundraising plans effectively, providing the necessary resources for its ongoing business operations and growth initiatives.

Mantra Capital Limited (formerly Savani Financials Limited) has announced the successful completion of its Capital and Fundraising Committee meeting on January 12, 2026, where key decisions regarding private placement of non-convertible debentures were approved. The meeting, which commenced at 4:30 PM and concluded at 8:15 PM, addressed important fundraising initiatives for the company.

Committee Approvals and NCD Details

The committee approved a comprehensive private placement offer for non-convertible debentures with attractive terms for investors. The approved structure demonstrates the company's strategic approach to debt fundraising.

Debenture Trustee Appointment

As part of the comprehensive approval process, the committee appointed Beacon Trusteeship Limited as the debenture trustee for the NCD issuance. This appointment ensures proper oversight and protection of debenture holders' interests throughout the tenure of the securities.

Regulatory Compliance

The announcement was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure follows the company's earlier intimation dated November 12, 2025, indicating a structured approach to the fundraising process.

Company Information

Mantra Capital Limited, previously known as Savani Financials Limited, operates under CIN L67120MH1983PLC031614. The company maintains its registered office at 602, Samarth Vaibhav CHS Ltd., Off Link Road, Lokhandwala Complex, Andheri (West), Mumbai - 400053. The formal communication was signed by Managing Director Deepa Tracy (DIN: 00516615) and submitted to BSE Limited for regulatory compliance.